Technical Title: A Study Evaluating the Safety and Effectiveness of AB928-BasedTreatment Combinations in Patients with mCRPC
A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating the Efficacy and Safety of AB928-Based Treatment Combinations in Patients with Metastatic Castrate Resistant Prostate Cancer
Disease Type: Metastatic, castration-resistant prostate cancer (mCRPC)
Basic information: The purpose of this study is to see if the addition of the study drug, AB928 with zimberelimab (AB122) combined with drugs that are approved by the US Food and Drug Administration (FDA) to treat mCRPC.
Research Procedures (not a complete list): Once you begin treatment, you will need to come to clinic every 2 weeks for approximately the first 4 months, then every 4 weeks through approximately the first year, and then approximately every 8 weeks until study treatment is stopped. You will also need to return for scans approximately every 8 weeks.
Eligibility Criteria (Not a complete list):
For More Detailed Information, Contact: